Keynote: Redefining Pharma–Biotech Alliances in a Volatile World

Session details:

Global markets are unstable, pipelines are more competitive, and R&D costs are rising. This keynote explores how top dealmakers are adapting partnership strategy to thrive amid economic and regulatory risk.

·       Better understand how biotech must now align to pharma's risk-mitigation expectations from the outset

·       Explore how partnerships are being designed to absorb market shocks—not just deliver milestones

·       Uncover the new metrics being used to gauge alliance success over time